Analysis of Body Mass Index in Central Precocious Puberty Patients Treated With Leuprolide Acetate

Inclusion Criteria: 1. Child diagnosed with CPP who has a peak-stimulated Lutenizing Hormone(LH) concentration over 5 IU/liter before initiation of therapy 2. Chronological age(CA) at the appearance of pubertal changes less than 8 years in girls and less than 9 years in boys. 3. Tanner stage ≥2 4. Advanced bone age (Bone Age/Chronological Age \>1.1) 5. Able to have the signed written informed consent provided by the patients' parents or legal guardians prior to any study-related procedures Exclusion Criteria: 1. Patient with a peripheral precocious puberty: extrapituitary secretion of gonadotropins or gonadotropin-independent gonadal or adrenal sex steroids secretion 2. Patient with a cerebral tumor requiring a neurosurgery or cerebral irradiation known chronic disease of underlying medical condition 3. Currently on or planning growth hormone treatment 4. Previous Gonadotropin-Releasing Hormone agonist treatment 5. Any patient who in opinion of the investigator should not participate in the study